IQVIA
IQVIA Holdings Inc. (NYSE: IQV) is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. The company operates at www.iqvia.com and serves as a critical partner throughout the pharmaceutical development and… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What IQVIA does
In the company’s own words
IQVIA Holdings Inc. (NYSE: IQV) is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. The company operates at www.iqvia.com and serves as a critical partner throughout the pharmaceutical development and commercialization lifecycle.
IQVIA maintains one of the largest and most comprehensive collections of healthcare information globally, encompassing more than 1.2 billion comprehensive, longitudinal, unique non-identified patient records. The company's proprietary data set spans approximately 68 petabytes of information sourced from approximately 150,000 data suppliers and covering over one million data feeds worldwide. This information foundation enables IQVIA to deliver insights on approximately 90 percent of the world's pharmaceuticals by sales volume.
The company operates through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Effective January 1, 2026, the company reorganized into Commercial Solutions and Research & Development Solutions segments. Technology & Analytics Solutions provides cloud-based SaaS applications, real-world evidence platforms, analytics and consulting services, and information offerings across more than 100 countries. Research & Development Solutions delivers clinical trial support, laboratory services, patient recruitment, and strategic planning capabilities. Contract Sales & Medical Solutions offers healthcare provider engagement, patient engagement programs, and medical services to support product commercialization.
IQVIA employs approximately 89,000 people across more than 100 countries, including over 31,000 Technology & Analytics Solutions employees, approximately 51,000 Research & Development Solutions employees, and approximately 7,000 Contract Sales & Medical Solutions employees. The company serves a diversified client base exceeding 10,000 customers, with nearly all of the top 100 global pharmaceutical and biotechnology companies as clients. No single client represents more than 10 percent of total revenues.
The company addresses a market opportunity estimated at approximately $335 billion, consisting of outsourced research and development, real-world evidence and connected health, and technology-enabled clinical and commercial operations markets. IQVIA's competitive advantages include its proprietary healthcare data infrastructure, advanced analytics capabilities, global presence, domain expertise, and integrated service offerings that enable clients to reduce development timelines and improve operational efficiency.
Company details
- Sector
- Health Care
- Industry (SIC)
- Professional Services
- Headquarters
- DURHAM, NC
- Fiscal year end
- December
- CIK
- 1478242
- SIC
- 8731
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns IQVIA — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in IQVIA · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · IQVIA’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
IQVIA’s bonds, as funds hold them
Funds report holding 8 issues of IQVIA’s debt, $2.31B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 5.79%, maturing 2026 to 2033.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do IQVIA and its peers compare on margins and cash generation over ten years?”
- “Where did five years of IQVIA's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in IQVIA's last four quarterly filings that the numbers alone won't show?”